Nektar Therapeutics (NASDAQ:NKTR) Shares Down 5.7% - Should You Sell?

Key Points

• Nektar shares fell 5.7% to $44.32 despite encouraging Phase 2b results for rezpegaldesleukin, which showed durable responses in alopecia areata and atopic dermatitis after treatment ended.
• The company is advancing rezpegaldesleukin toward pivotal testing, with a third Phase 3 atopic dermatitis trial underway and an alopecia areata Phase 3 study expected in early 2027.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $138.50, but investors may be awaiting definitive Phase 3 evidence and a clearer path to commercialization.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report)'s share price was down 5.7% during mid-day trading on Friday. The stock traded as low as $44.76 and last traded at $44.32. 1,013,856 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 1,077,279 shares. The stock had previously closed at $46.99.

Nektar Therapeutics News Summary

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Long-term Phase 2b results showed that rezpegaldesleukin’s benefits may persist after treatment ends. In alopecia areata, 75% of responding patients maintained a SALT score of 20 or below four months off treatment, while 63% maintained that response at six months. Hair regrowth also continued after treatment, with 19% reaching a SALT score of 10 or below. New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement
• Positive Sentiment: Nektar is advancing the program toward pivotal testing: a third Phase 3 ZENITH trial in treatment-experienced atopic dermatitis has begun, and the Phase 3 ZENITH alopecia areata study is expected to start in early 2027. Nektar Reports Durable Rezpegaldesleukin Data
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and assigned a $185 price target, implying substantial upside from recent trading levels. This is an analyst forecast, not a guarantee of performance.
• Neutral Sentiment: New biomarker findings indicated early effects across multiple immune pathways in atopic dermatitis, potentially supporting rezpegaldesleukin’s differentiated Treg-based mechanism. New Biomarker Data Presented at EADV Congress 2026
• Negative Sentiment: The positive dermatology update did not immediately translate into a stronger stock reaction. Investors may be demanding clearer pivotal-trial evidence and a nearer-term commercial path, since the reported results are still Phase 2b data and Phase 3 readouts remain outstanding. Nektar Drops After New Mid-Stage Data

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on NKTR. Canaccord Genuity Group started coverage on Nektar Therapeutics in a research report on Wednesday, July 22nd. They set a "buy" rating and a $153.00 price objective for the company. TD Cowen raised Nektar Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. HC Wainwright reiterated a "buy" rating and issued a $185.00 price target on shares of Nektar Therapeutics in a research report on Friday. BTIG Research reissued a "buy" rating and issued a $178.00 price target on shares of Nektar Therapeutics in a research note on Friday, September 25th. Finally, JPMorgan Chase & Co. started coverage on shares of Nektar Therapeutics in a research note on Friday, August 21st. They set a "neutral" rating and a $65.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $138.50.

Nektar Therapeutics Price Performance

The stock has a fifty day moving average price of $70.09 and a 200-day moving average price of $71.25. The company has a market cap of $1.51 billion, a PE ratio of -6.64 and a beta of 1.26.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, beating analysts' consensus estimates of ($1.97) by $0.74. The business had revenue of $10.13 million for the quarter, compared to the consensus estimate of $10.43 million. Nektar Therapeutics had a negative return on equity of 37.87% and a negative net margin of 287.84%. On average, equities analysts anticipate that Nektar Therapeutics will post -8.16 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Howard Robin sold 418 shares of the company's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $30,087.64. Following the transaction, the chief executive officer owned 54,627 shares in the company, valued at $3,932,051.46. This represents a 0.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV bought a new stake in Nektar Therapeutics during the first quarter worth approximately $52,000. FNY Investment Advisers LLC raised its position in shares of Nektar Therapeutics by 15.8% in the second quarter. FNY Investment Advisers LLC now owns 5,500 shares of the biopharmaceutical company's stock valued at $383,000 after purchasing an additional 750 shares during the period. State of Wyoming bought a new position in shares of Nektar Therapeutics in the first quarter valued at approximately $67,000. Arizona State Retirement System lifted its stake in shares of Nektar Therapeutics by 27.3% in the second quarter. Arizona State Retirement System now owns 8,477 shares of the biopharmaceutical company's stock worth $592,000 after buying an additional 1,816 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Nektar Therapeutics by 32.5% during the 1st quarter. Janus Henderson Group PLC now owns 10,729 shares of the biopharmaceutical company's stock worth $771,000 after buying an additional 2,629 shares during the period. 75.88% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that use the body's immune system to treat cancer and autoimmune diseases. The company's research programs are based on proprietary drug-design and immunology technologies intended to improve the activity, targeting, or dosing of therapeutic agents.

Nektar's pipeline has included NKTR-255, an investigational interleukin-15 receptor agonist designed to activate natural killer cells and support antitumor immune responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.